Claims for Patent: 8,114,394

Summary for Patent: 8,114,394

Title:	Use of IL-1 antagonists to treat gout
Abstract:	Methods of treating, inhibiting, or ameliorating gout, including chronic acute (refractory) gout, pseudogout, or drug-induced gout, in a human subject in need thereof, comprising administering to a subject in need a therapeutic amount of an interleukin 1 (IL-1) antagonist, wherein the incidence of a gout flare is reduced or inhibited.
Inventor(s):	Vicary; Catherine (New York, NY), Mellis; Scott (New Rochelle, NY)
Assignee:	Regeneron Pharmaceuticals, Inc. (Tarrytown, NY)
Application Number:	12/887,529
Patent Claims:	1. A method of reducing the occurrence of gout flares in a subject, said method comprising administering to the subject a course of treatment comprising an interleukin-1 (IL-1) antagonist once per week, wherein the subject is treated concurrently with a uric acid synthesis inhibitor. 2. The method of claim 1, wherein the uric acid synthesis inhibitor is allopurinol. 3. The method of claim 1, wherein the IL-1 antagonist is an IL-1 trap. 4. The method of claim 3, wherein the IL-1 trap is rilonacept. 5. The method of claim 2, wherein the IL-1 antagonist is an IL-1 trap. 6. The method of claim 5, wherein the IL-1 trap is rilonacept. 7. The method of claim 1, wherein the IL-1 antagonist is administered at an initial dose of about 80 mg to about 500 mg on the first day of treatment. 8. The method of claim 7, wherein the IL-1 antagonist is an IL-1 trap. 9. The method of claim 8, wherein the IL-1 trap is rilonacept. 10. The method of claim 9, wherein the rilonacept is administered at an initial dose of 320 mg on the first day of treatment. 11. The method of claim 7, wherein the IL-1 antagonist is administered at subsequent doses of about 40 mg to about 250 mg. 12. The method of claim 11, wherein the IL-1 antagonist is an IL-1 trap. 13. The method of claim 12, wherein the IL-1 trap is rilonacept. 14. The method of claim 13, wherein the rilonacept is administered at subsequent doses of 160 mg. 15. The method of claim 11, wherein the uric acid synthesis inhibitor is allopurinol. 16. The method of claim 12, wherein the uric acid synthesis inhibitor is allopurinol. 17. The method of claim 13, wherein the uric acid synthesis inhibitor is allopurinol. 18. The method of claim 14, wherein the uric acid synthesis inhibitor is allopurinol. 19. The method of claim 1, wherein the course of treatment is administered for 16 weeks. 20. The method of claim 1, wherein the IL-1 antagonist is administered subcutaneously.

Details for Patent 8,114,394

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Kiniksa Pharmaceuticals (uk), Ltd.	ARCALYST	rilonacept	For Injection	125249	02/27/2008		2026-10-20